Skip to main content

Leica Biosystems Launches BOND-PRIME Advanced Staining Solution to Accelerate Diagnostic Productivity

Powered by Universal Access, BOND-PRIME Enables Labs to Seamlessly Adapt to Any Incoming Workflows

NUSSLOCH, Germany (April 19) – Leica Biosystems announce the European launch of BOND-PRIME, a faster, more advanced staining solution. BOND-PRIME delivers all elements of Universal Access – able to handle any slide, in any combination, at any time, using any reagent.

Single or STAT slides can be turned around in one hour, enabling pathologists to deliver a diagnosis quickly, especially vital for patients needing urgent diagnostic decisions. Turnaround time (TAT) for the average immunohistochemistry (IHC) slide is shortened to an average 90 minutes, with 100% instrument utilization without the need for constant attention.

The BOND-PRIME staining solution seamlessly adapts and optimizes workflow to stain slides as needed, leaving no slide staining position unutilized. It offers 70 open-access reagent positions, with a total on-board capacity of 72 slides.

“In today’s fast-paced health care environment, adaptability is essential to ensure that slides are processed in a timely manner, without compromising on quality,” explained Colin White, Senior Vice President of Advanced Staining, and Imaging.

“BOND-PRIME is a generation ahead. It enables labs to achieve a high-speed, continuous workflow, an average single slide TAT of 90 minutes, no downtime and minimal need for manual intervention. The impact on quality and productivity is truly impressive.”

In addition to adaptability and speed, the platform incorporates novel technology to further enhance the quality of staining available to laboratories. This produces consistently crisp, clear stains that are gentle on sample tissue with minimal carry-over. Leica Biosystems developed Active Reagent Control (ARC) to make it possible to deliver a highly controlled reagent application and incubation.

“We have a history of innovation that addresses specific customer needs,” said Gustavo Perez-Fernandez, President at Leica Biosystems. “The BOND-PRIME staining solution presents a quantifiable benefit to mid-sized and large laboratories in terms of both quality and greater efficiency. STAT cases can be processed quickly and efficiently, without holding back the validation of more routine cases. By streamlining workflow, the use of BOND-PRIME ensures that fewer cases overall are left pending.”

BOND-PRIME is now available in specific countries in the EMEA regions as well as the United States, Canada, Australia, and New Zealand.

For In Vitro Diagnostic Use. BOND-PRIME may not be available in your region

About Leica Biosystems

Leica Biosystems is a cancer diagnostics company and a global leader in workflow solutions. Only Leica Biosystems offers the most comprehensive portfolio that spans the entire workflow from biopsy to diagnosis. With unique expertise, we are dedicated to driving innovations that connect people across radiology, pathology, surgery, and oncology. Our experts are committed to delivering Improved Quality, Integrated Solutions, and Optimized Efficiencies leading to breakthrough advances in diagnostic confidence. Our mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of our corporate culture. Visit for more information.

Lauren Meinhardt
Communications & Brand Director